453-34-9 Usage
General Description
4,4,4-Trifluoro-3-hydroxybutyramide is a chemical compound with the molecular formula C4H6F3NO2. It is a white crystalline solid with a molecular weight of 149.1 g/mol. 4,4,4-TRIFLUORO-3-HYDROXYBUTYRAMIDE is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also used as a reagent in organic synthesis and as a building block in the production of various fluorinated compounds. The presence of the trifluoro and hydroxy groups in its chemical structure makes it a valuable compound for the preparation of fluorinated pharmaceuticals and other biologically active molecules. Additionally, it has potential applications in the field of medicinal chemistry and drug discovery.
Check Digit Verification of cas no
The CAS Registry Mumber 453-34-9 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 4,5 and 3 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 453-34:
(5*4)+(4*5)+(3*3)+(2*3)+(1*4)=59
59 % 10 = 9
So 453-34-9 is a valid CAS Registry Number.
InChI:InChI=1/C4H6F3NO2/c5-4(6,7)2(9)1-3(8)10/h2,9H,1H2,(H2,8,10)
453-34-9Relevant articles and documents
CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS
-
Page/Page column 338, (2021/04/10)
The disclosure includes compounds of Formula (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1 Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.
BCL-2 INHIBITORS
-
Page/Page column 235, (2020/03/15)
The disclosure includes compounds of Formula (A), (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1, Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.
Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection
-
Paragraph 0467-0468, (2016/08/17)
The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds.
